FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ian Smith

Research Profile

Disorders

Procedures

Concepts & Ideas

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Anita K Dunbier; Zara Ghazoui; William R Miller; Ashutosh Nerurkar; Peter Osin; Janine Salter; Ian E Smith; Roger A'Hern; Helen Anderson; Mitch Dowsett
Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance.
BP Haynes; Nicole Rotmensz; Ian E Smith; Giuseppe Viale; Roger A'Hern; Viviana Galimberti; Bianca Gibelli; Mitch Dowsett
Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer.
Gaia Schiavon; Tim W R Briggs; Diana M Tait; Ian E Smith
A solitary bone lesion in a patient with previous breast cancer and the importance of bone biopsy: a case report and a review of guidelines.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ian Smith (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Anita K Dunbier; Zara Ghazoui; William R Miller; Ashutosh Nerurkar; Peter Osin; Janine Salter; Ian E Smith; Roger A'Hern; Helen Anderson; Mitch Dowsett
Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(10):2775-86.
2013: BP Haynes; Nicole Rotmensz; Ian E Smith; Giuseppe Viale; Roger A'Hern; Viviana Galimberti; Bianca Gibelli; Mitch Dowsett
Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer.
Breast cancer research and treatment 2013;138(1):157-65.
2013: Gaia Schiavon; Tim W R Briggs; Diana M Tait; Ian E Smith
A solitary bone lesion in a patient with previous breast cancer and the importance of bone biopsy: a case report and a review of guidelines.
Clinical breast cancer 2013;13(1):77-80.
2013: M Wong; G Walsh; S O'Neill; Ian E Smith
Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24(1):133-8.
2011: Mitch Dowsett; Matthew Ellis; Daniel F Hayes; N Lynn Henry; Judith C Hugh; Tracy Lively; Lisa McShane; Torsten O Nielsen; Soon Paik; Frederique Penault-Llorca; Ljudmila Prudkin; Meredith Regan; Janine Salter; Ian E Smith; Christos Sotiriou; Giuseppe Viale; Jo Anne Zujewski; Roger A'Hern; John Bartlett; R Charles Coombes; Jack Cuzick
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.
Journal of the National Cancer Institute 2011;103(22):1656-64.
2011: Sarah R Barton; Anna M Kirby; Ian E Smith; Geraldine Walsh; Sue Ashley; Marina Parton
The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy.
European journal of cancer (Oxford, England : 1990) 2011;47(14):2099-106.
2011: H Anderson; Roger A'Hern; BP Haynes; Margaret Hills; A F Leary; Ian E Smith; Lila Zabaglo; Mitch Dowsett
Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(8):1770-6.
2011: Anita K Dunbier; Zara Ghazoui; Joel Parker; Charles M Perou; Janine Salter; Ian E Smith; Helen Anderson; Mitch Dowsett
Association between breast cancer subtypes and response to neoadjuvant anastrozole.
Steroids 2011;76(8):736-40.
2011: Zara Ghazoui; Francesca M Buffa; Anita K Dunbier; Helen Anderson; Tim Dexter; Simone Detre; Janine Salter; Ian E Smith; Adrian L Harris; Mitchell Dowsett
Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(9):3005-12.
2011: Ian E Smith; J-Y Pierga; L Biganzoli; H Cortés-Funes; C Thomssen; X Pivot; A Fabi; B Xu; D Stroyakovskiy; F A Franke; B Kaufman; P Mainwaring; T Pienkowski; B De Valk; A Kwong; J L González-Trujillo; I Koza; K Petrakova; D Pereira; K I Pritchard
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(3):595-602.
2011: Robin L Jones; Federico Rojo; Roger A'Hern; Nadia Villena; Janine Salter; Josep Maria Corominas; Sonia Servitja; Ian E Smith; Ana Rovira; Jorge S Reis-Filho; Mitchell Dowsett; Joan Albanell
Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer.
Journal of clinical pathology 2011;64(2):130-5.
2010: Susana Banerjee; Ian E Smith
Management of small HER2-positive breast cancers.
The lancet oncology 2010;11(12):1193-9.
2010: A A Kotsori; J L Noble; Sue Ashley; S Johnston; Ian E Smith
Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first line treatment?
Breast (Edinburgh, Scotland) 2010;19(5):377-81.
2010: BP Haynes; Anne Hege Straume; Jürgen Geisler; Roger A'Hern; Hildegunn Helle; Ian E Smith; Per E Lønning; Mitch Dowsett
Intratumoral estrogen disposition in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(6):1790-801.
2010: Anita K Dunbier; Helen Anderson; Zara Ghazoui; Elizabeth Folkerd; Roger A'Hern; Robert J Crowder; Jeremy Hoog; Ian E Smith; Peter Osin; Ashutosh Nerurkar; Joel Parker; Charles M Perou; Matthew J Ellis; Mitch Dowsett
Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(7):1161-7.
2010: Isabel F Pinhel; Janine Salter; Ian E Smith; Roger A'Hern; Simone Detre; Margaret J Hills; Fiona A Macneill; Ashutosh Nerurkar; Peter Osin; Mitch Dowsett
Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer.
Breast cancer research : BCR 2010;12(5):R76.
2010: Robin L Jones; Janine Salter; Roger A'Hern; Ashutosh Nerurkar; Marina Parton; Jorge S Reis-Filho; Ian E Smith; Mitchell Dowsett
Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.
Breast cancer research and treatment 2010;119(2):315-23.
2009: Ian E Smith; Susana Banerjee
The follow-up of women at high risk for breast cancer relapse.
Breast (Edinburgh, Scotland) 2009;18 Suppl 3():S74-7.
2009: Ian E Smith
Targeting HER2 in the adjuvant setting: dealing with new standards and with open questions.
Breast (Edinburgh, Scotland) 2009;18 Suppl 3():S146-9.
2009: Robin L Jones; Janine Salter; Roger A'Hern; Ash Nerurkar; Marina Parton; Jorge S Reis-Filho; Ian E Smith; Mitchell Dowsett
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer.
Breast cancer research and treatment 2009;116(1):53-68.
2009: Mitch Dowsett; Roger A'Hern; Janine Salter; Lila Zabaglo; Ian E Smith
Who would have thought a single Ki67 measurement would predict long-term outcome?
Breast cancer research : BCR 2009;11 Suppl 3():S15.
2008: Ander Urruticoechea; Monica Arnedos; Geraldine Walsh; Mitch Dowsett; Ian E Smith
Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC).
Breast cancer research and treatment 2008;110(3):411-6.
2008: Stephen R D Johnston; Alex Leary; Lesley-Ann Martin; Ian E Smith; Mitch Dowsett
Enhancing endocrine response with novel targeted therapies: why have the clinical trials to date failed to deliver on the preclinical promise?
Cancer 2008;112(3 Suppl):710-7.
2008: Ian E Smith
Neoadjuvant/presurgical treatments.
Breast cancer research : BCR 2008;10 Suppl 4():S24.
2007: Ian E Smith; Monica Arnedos
The evolution of adjuvant endocrine therapy: developments since St Gallen 2005.
Breast (Edinburgh, Scotland) 2007;16 Suppl 2():S4-9.
2007: Ian E Smith; Geraldine Walsh; Anthony Skene; Antonio Llombart; José I Mayordomo; Simone Detre; Janine Salter; Emma Clark; Patrick Magill; Mitch Dowsett
A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(25):3816-22.
2007: Trevor J Powles; Sue Ashley; Alwynne Tidy; Ian E Smith; Mitch Dowsett
Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
Journal of the National Cancer Institute 2007;99(4):283-90.
2007: J-Y Pierga; Jorge S Reis-Filho; Susan J Cleator; Tim Dexter; Alan Mackay; P Simpson; Kerry Fenwick; Marjan Iravani; Janine Salter; Margaret Hills; Chris Jones; Alan Ashworth; Ian E Smith; T Powles; Mitch Dowsett
Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy.
British journal of cancer 2007;96(2):341-51.
2007: Mitch Dowsett; Ian E Smith; Steve R Ebbs; J Michael Dixon; Anthony Skene; Roger A'Hern; Janine Salter; Simone Detre; Margaret Hills; Geraldine Walsh
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
Journal of the National Cancer Institute 2007;99(2):167-70.
2006: M E R O'Brien; A Borthwick; A Rigg; Alex Leary; Laura Assersohn; K Last; S Tan; Sarah Milan; Diana Tait; Ian E Smith
Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients.
British journal of cancer 2006;95(12):1632-6.
2006: R L Jones; Sunil R Lakhani; A E Ring; Sue Ashley; G Walsh; Ian E Smith
Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma.
British journal of cancer 2006;94(3):358-62.
2006: Mitch Dowsett; Ian E Smith; Steve R Ebbs; J Michael Dixon; Anthony Skene; Clive Griffith; Irene Boeddinghaus; Janine Salter; Simone Detre; Margaret Hills; Sue Ashley; Stephen Francis; Geraldine Walsh; Roger A'Hern
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(3 Pt 2):1024s-1030s.
2006: Susan J Cleator; Trevor J Powles; Tim Dexter; Laura G Fulford; Alan Mackay; Ian E Smith; Haukur Valgeirsson; Alan Ashworth; Mitch Dowsett
The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis.
Breast cancer research : BCR 2006;8(3):R32.
2005: Ander Urruticoechea; Ian E Smith; Mitch Dowsett
Proliferation marker Ki-67 in early breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(28):7212-20.
2005: Ian E Smith; Susan G Cross
Trastuzumab.
Women's health (London, England) 2005;1(2):161-9.
2005: S Chua; Ian E Smith; Roger P A'Hern; Gill Coombes; Tamas Hickish; A C Robinson; R W Laing; M E R O'Brien; Steven R Ebbs; A Hong; Andrew M Wardley; T Mughal; Mark Verrill; D Dubois; Judith M Bliss
Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(9):1435-41.
2005: Ian E Smith; Mitch Dowsett; Steve R Ebbs; J Michael Dixon; Anthony Skene; J-U Blohmer; Susan E Ashley; Stephen Francis; Irene Boeddinghaus; Geraldine Walsh
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(22):5108-16.
2005: Mitch Dowsett; Steve R Ebbs; J Michael Dixon; Anthony Skene; Clive Griffith; Irene Boeddinghaus; Janine Salter; Simone Detre; Margaret Hills; Sue Ashley; Stephen Francis; Geraldine Walsh; Ian E Smith
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(11):2477-92.
2005: Alistair Ring; Lila Zabaglo; Michael G Ormerod; Ian E Smith; Mitch Dowsett
Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques.
British journal of cancer 2005;92(5):906-12.
2005: Ander Urruticoechea; CD Archer; Laura Assersohn; RK Gregory; Mark Verrill; R Mendes; Geraldine Walsh; Ian E Smith; Stephen R D Johnston
Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer.
British journal of cancer 2005;92(3):475-9.
2005: Mitch Dowsett; Ian E Smith; Steve R Ebbs; J Michael Dixon; Anthony Skene; Clive Griffith; Irene Boeddinghaus; Janine Salter; Simone Detre; Margaret Hills; Sue Ashley; Stephen Francis; Geraldine Walsh
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 2):951s-8s.
2004: A E Ring; Ian E Smith; S Ashley; Laura G Fulford; Sunil R Lakhani
Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer.
British journal of cancer 2004;91(12):2012-7.
2004: Eleni Andreopoulou; Paul J Ross; M E R O'Brien; Hugo Ford; Kathy Priest; Tim Eisen; Alison Norton; Sue Ashley; Ian E Smith
The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(9):1406-12.
2004: Paul J Ross; Sue Ashley; Alison Norton; Kathy Priest; Justin S Waters; Tim Eisen; Ian E Smith; M E R O'Brien
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?
British journal of cancer 2004;90(10):1905-11.
2004: Ian E Smith; Roger P A'Hern; Gill Coombes; A Howell; Steven R Ebbs; Tamas Hickish; M E R O'Brien; Janine L Mansi; C B Wilson; A C Robinson; P A Murray; C G A Price; Timothy J Perren; R W Laing; Judith M Bliss
A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(5):751-8.
2004: M Parton; M Dowsett; Sue Ashley; M Hills; F Lowe; Ian E Smith
High incidence of HER-2 positivity in inflammatory breast cancer.
Breast (Edinburgh, Scotland) 2004;13(2):97-103.
2004: Alistair Ring; Ian E Smith; Mitch Dowsett
Circulating tumour cells in breast cancer.
The lancet oncology 2004;5(2):79-88.
2003: A Ring; A Webb; Sue Ashley; WH Allum; Steve R Ebbs; G P H Gui; Nigel Sacks; Geraldine Walsh; Ian E Smith
Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(24):4540-5.
2003: PV Murray; M E R O'Brien; R Sayer; N Cooke; G Knowles; A C Miller; V Varney; N P Rowell; Anwar R Padhani; DA MacVicar; Alison Norton; Sue Ashley; Ian E Smith
The pathway study: results of a pilot feasibility study in patients suspected of having lung carcinoma investigated in a conventional chest clinic setting compared to a centralised two-stop pathway.
Lung cancer (Amsterdam, Netherlands) 2003;42(3):283-90.
2003: Lila Zabaglo; Michael G Ormerod; Marina Parton; Alistair Ring; Ian E Smith; Mitch Dowsett
Cell filtration-laser scanning cytometry for the characterisation of circulating breast cancer cells.
Cytometry. Part A : the journal of the International Society for Analytical Cytology 2003;55(2):102-8.
2003: CD Archer; M Parton; Ian E Smith; PA Ellis; Janine Salter; Sue Ashley; G P H Gui; Nigel Sacks; Steve R Ebbs; WH Allum; Nazar Nasiri; Mitch Dowsett
Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer.
British journal of cancer 2003;89(6):1035-41.
2003: Ian E Smith
Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy.
The Journal of steroid biochemistry and molecular biology 2003;86(3-5):289-93.
2003: Ian E Smith; Mitch Dowsett
Aromatase inhibitors in breast cancer.
The New England journal of medicine 2003;348(24):2431-42.
2003: Stephen R D Johnston; Julia Head; Sunil Pancholi; Simone Detre; Lesley-Ann Martin; Ian E Smith; Mitch Dowsett
Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1 Pt 2):524S-32S.
2002: Ian E Smith
New drugs for breast cancer.
Lancet 2002;360(9335):790-2.
2002: RH de Boer; Tim Eisen; P A Ellis; Stephen R D Johnston; Geraldine Walsh; Sue Ashley; Ian E Smith
A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(6):889-94.
2002: Laura Assersohn; BE Souberbielle; M E R O'Brien; C D Archer; R Mendes; R Bass; KV Bromelow; R D Palmer; E Bouilloux; D A Kennard; Ian E Smith
A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy.
Clinical oncology (Royal College of Radiologists (Great Britain)) 2002;14(1):23-7.
2002: R Mendes; M E R O'Brien; A Mitra; A Norton; RK Gregory; A R Padhani; KV Bromelow; A R Winkley; S Ashley; Ian E Smith; BE Souberbielle
Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma.
British journal of cancer 2002;86(3):336-41.
2001: Ian E Smith; M E R O'Brien; Denis C Talbot; Marianne Nicolson; Janine L Mansi; Tamas Hickish; A Norton; Sue Ashley
Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1336-43.
2001: RK Gregory; Ian E Smith; A Norton; S Ashley; M E R O'Brien
Mitomycin C, vinblastine and carboplatin: effective outpatient chemotherapy for advanced non-small cell carcinoma of the lung (NSCLC).
Clinical oncology (Royal College of Radiologists (Great Britain)) 2001;13(6):483-7.
2001: KV Bromelow; W Hirst; R L Mendes; A R Winkley; Ian E Smith; M E R O'Brien; BE Souberbielle
Whole blood assay for assessment of the mixed lymphocyte reaction.
Journal of immunological methods 2001;247(1-2):1-8.
2000: PV Murray; thierry soussi; M E R O'Brien; Ian E Smith; S Brossault; Alison Norton; Sue Ashley; M Tavassoli
Serum p53 antibodies: predictors of survival in small-cell lung cancer?
British journal of cancer 2000;83(11):1418-24.
2000: M E R O'Brien; A Saini; Ian E Smith; A Webb; K Gregory; R Mendes; C Ryan; Kathy Priest; KV Bromelow; R D Palmer; N Tuckwell; D A Kennard; BE Souberbielle
A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma.
British journal of cancer 2000;83(7):853-7.
2000: RH de Boer; WH Allum; Steve R Ebbs; G P H Gui; Stephen R D Johnston; Nigel Sacks; Geraldine Walsh; Sue Ashley; Ian E Smith
Multimodality therapy in inflammatory breast cancer: is there a place for surgery?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(9):1147-53.
2000: RH de Boer; A Saini; Stephen R D Johnston; M E R O'Brien; P A Ellis; Mark Verrill; JA Prendiville; Geraldine Walsh; Sue Ashley; Ian E Smith
Continuous infusional combination chemotherapy in inflammatory breast cancer: a phase II study.
Breast (Edinburgh, Scotland) 2000;9(3):149-55.
2000: R K Gregory; Ian E Smith
Vinorelbine--a clinical review.
British journal of cancer 2000;82(12):1907-13.
2000: Ian E Smith; Stephen R D Johnston; M E R O'Brien; Tamas Hickish; RH de Boer; A Norton; D T Cirkel; C M Barton
Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(12):2378-84.
2000: Tim Eisen; C Boshoff; Ian Mak; F Sapunar; MM Vaughan; Lynda Pyle; Stephen R D Johnston; Roger Ahern; Ian E Smith; Martin E Gore
Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer.
British journal of cancer 2000;82(4):812-7.
2000: R Mendes; KV Bromelow; M Westby; Joanna Galea-Lauri; Ian E Smith; M E R O'Brien; BE Souberbielle
Flow cytometric visualisation of cytokine production by CD3-CD56+ NK cells and CD3+CD56+ NK-T cells in whole blood.
Cytometry 2000;39(1):72-8.
1999: Mitch Dowsett; CD Archer; Laura Assersohn; RK Gregory; PA Ellis; Janine Salter; J Chang; PN Mainwaring; Irene Boeddinghaus; Stephen R D Johnston; Trevor J Powles; Ian E Smith
Clinical studies of apoptosis and proliferation in breast cancer.
Endocrine-related cancer 1999;6(1):25-8.
1999: RH de Boer; Ian E Smith; U Pastorino; M E R O'Brien; F Ramage; Sue Ashley; P Goldstraw
Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer: a randomized feasibility study justifying a multicentre phase III trial.
British journal of cancer 1999;79(9-10):1514-8.
1999: Stephen R D Johnston; B Lu; Gary K Scott; P J Kushner; Ian E Smith; Mitch Dowsett; Christopher C Benz
Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(2):251-6.
1998: Mitch Dowsett; Simone Detre; Michael G Ormerod; PA Ellis; PN Mainwaring; Jenny Titley; Ian E Smith
Analysis and sorting of apoptotic cells from fine-needle aspirates of excised human primary breast carcinomas.
Cytometry 1998;32(4):291-300.
1998: Tamas Hickish; Ian E Smith; M E R O'Brien; Sue Ashley; Gary Middleton
Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors.
British journal of cancer 1998;78(1):28-33.
1998: Tamas Hickish; Ian E Smith; Marianne Nicolson; Sue Ashley; Kathy Priest; L Spencer; Andy Norman; Gary Middleton; M E R O'Brien
A pilot study of MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in small-cell lung cancer.
British journal of cancer 1998;77(11):1966-70.
1998: Tim Eisen; Ian E Smith; S Johnston; P A Ellis; JA Prendiville; Matt Seymour; Geraldine Walsh; Sue Ashley
Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(4):1350-7.
1998: Gary Middleton; Ian E Smith; M E R O'Brien; Alison Norton; Tamas Hickish; Kathy Priest; L Spencer; Sue Ashley
Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(3):269-73.
1998: PA Ellis; Ian E Smith; Simone Detre; S A Burton; Janine Salter; Roger A'Hern; Geraldine Walsh; Stephen R D Johnston; Mitch Dowsett
Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy.
Breast cancer research and treatment 1998;48(2):107-16.
1998: PN Mainwaring; PA Ellis; Simone Detre; Ian E Smith; Mitch Dowsett
Comparison of in situ methods to assess DNA cleavage in apoptotic cells in patients with breast cancer.
Journal of clinical pathology 1998;51(1):34-7.
1997: PA Ellis; G Saccani-Jotti; R Clarke; Stephen R D Johnston; E Anderson; A Howell; Roger A'Hern; Janine Salter; Simone Detre; R Nicholson; J Robertson; Ian E Smith; Mitch Dowsett
Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer.
International journal of cancer. Journal international du cancer 1997;72(4):608-13.
1997: PA Ellis; Ian E Smith; K McCarthy; Simone Detre; J Salter; Mitch Dowsett
Preoperative chemotherapy induces apoptosis in early breast cancer.
Lancet 1997;349(9055):849.
1997: P N Mainwaring; Marianne Nicolson; Tamas Hickish; Richard T Penson; Simon P Joel; Maurice L Slevin; Ian E Smith
Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy.
British journal of cancer 1997;76(12):1636-9.
1996: H Bonnefoi; Ian E Smith
How should cancer presenting as a malignant pleural effusion be managed?
British journal of cancer 1996;74(5):832-5.
1996: Ian E Smith
Prophylactic cranial irradiation for small-cell lung cancer.
Lancet 1996;348(9024):350.
1996: PA Ellis; Ian E Smith; Mitch Dowsett
Apoptosis--its role in tumour growth and therapy.
Cytopathology : official journal of the British Society for Clinical Cytology 1996;7(3):201-3.
1996: Mitch Dowsett; A Makris; P Ellis; Stephen R D Johnston; Janine Salter; Simone Detre; S Humphries; G Saccani-Jotti; Trevor J Powles; Ian E Smith
Oncogene products and other diagnostic markers in human breast cancer patients. Treatment effects and their significance.
Annals of the New York Academy of Sciences 1996;784():403-11.
1996: PA Ellis; A Makris; S A Burton; Jenny Titley; Michael G Ormerod; Janine Salter; Trevor J Powles; Ian E Smith; Mitch Dowsett
Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas.
British journal of cancer 1996;73(5):640-3.
1996: H Bonnefoi; Ian E Smith; M E O'Brien; M T Seymour; Trevor J Powles; W H Allum; S Ebbs; Michael Baum
Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen.
British journal of cancer 1996;73(3):391-6.
1995: P A Ellis; Denis C Talbot; Kathy Priest; A L Jones; Ian E Smith
Dose intensification of carboplatin and etoposide as first-line combination chemotherapy in small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 1995;31A(11):1888-9.
1995: Tamas Hickish; Ian E Smith; S Ashley; Gary Middleton
Chemotherapy for elderly patients with lung cancer.
Lancet 1995;346(8974):580.
1995: Stephen R D Johnston; G Saccani-Jotti; Ian E Smith; Janine Salter; J Newby; M Coppen; S R Ebbs; Mitch Dowsett
Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.
Cancer research 1995;55(15):3331-8.
1995: P A Ellis; Denis C Talbot; M C Nicolson; Kathy Priest; Sue Ashley; Ian E Smith
A pilot study of mitomycin, cisplatin and continuous infusion 5-fluorouracil (MCF) in advanced non-small-cell lung cancer.
British journal of cancer 1995;71(6):1315-8.
1995: J C Newby; Roger A'Hern; R D Leek; Ian E Smith; A L Harris; Mitch Dowsett
Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer.
British journal of cancer 1995;71(6):1237-42.
1995: Tamas Hickish; Ian E Smith; Gary Middleton; M Nicolson
Patient preference for extended palliative chemotherapy for non-small cell lung cancer.
Lancet 1995;345(8953):857-8.
1995: Ian E Smith; Geraldine Walsh; A Jones; J Prendiville; S Johnston; Barry A Gusterson; F Ramage; H Robertshaw; N Sacks; S Ebbs
High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(2):424-9.
1995: P A Ellis; Ian E Smith; J R Hardy; M C Nicolson; Denis C Talbot; SE Ashley; Kathy Priest
Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer.
British journal of cancer 1995;71(2):366-70.
1995: A A Daffada; Stephen R D Johnston; Ian E Smith; Simone Detre; N King; Mitch Dowsett
Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer.
Cancer research 1995;55(2):288-93.
1995: Ian E Smith
Protracted infusional chemotherapy in breast cancer: the Royal Marsden Hospital experience.
The Journal of infusional chemotherapy 1995;5(4):206-7.
1995: Ian E Smith
Medical management of non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 1995;31A(5):818-9.
1994: S R Johnston; Ian E Smith; D Doody; S Jacobs; H Robertshaw; M Dowsett
Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.
Cancer research 1994;54(22):5875-81.
1994: A L Jones; Ian E Smith; M E O'Brien; D Talbot; Geraldine Walsh; F Ramage; H Robertshaw; Sue Ashley
Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(6):1259-65.
1994: Stephen R D Johnston; K A MacLennan; N P Sacks; Janine Salter; Ian E Smith; Mitch Dowsett
Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen.
European journal of cancer (Oxford, England : 1990) 1994;30A(11):1663-9.
1994: M Dowsett; D Smithers; J Moore; P F Trunet; R C Coombes; T J Powles; R Rubens; Ian E Smith
Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer.
European journal of cancer (Oxford, England : 1990) 1994;30A(10):1453-8.
1993: Stephen R D Johnston; BP Haynes; Ian E Smith; Michael Jarman; N P Sacks; S R Ebbs; Mitch Dowsett
Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration.
Lancet 1993;342(8886-8887):1521-2.
1993: Stephen R D Johnston; BP Haynes; N P Sacks; J A McKinna; L J Griggs; Michael Jarman; Michael Baum; Ian E Smith; Mitch Dowsett
Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer.
Breast cancer research and treatment 1993;28(3):241-50.
1993: A L Jones; J Holborn; Sue Ashley; Ian E Smith
CVM versus ACE in the treatment of small cell lung cancer.
Oncology 1993;50 Suppl 2():10-5.
1993: M E O'Brien; Denis C Talbot; Ian E Smith
Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(11):2112-7.
1993: Tamas Hickish; A Roldan; David Cunningham; J Mansi; Sue Ashley; V Nicolson; M E Gore; D Catovsky; Ian E Smith
EPIC: an effective low toxicity regimen for relapsing lymphoma.
British journal of cancer 1993;68(3):599-604.
1993: T J Iveson; Ian E Smith; J Ahern; D A Smithers; P F Trunet; M Dowsett
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women.
The Journal of clinical endocrinology and metabolism 1993;77(2):324-31.
1993: Ian E Smith; Trevor J Powles
MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer.
Oncology 1993;50 Suppl 1():9-15.
1993: Mitch Dowsett; V Macaulay; J Gledhill; C Ryde; J Nicholls; Alan Ashworth; J A McKinna; Ian E Smith
Control of aromatase in breast cancer cells and its importance for tumor growth.
The Journal of steroid biochemistry and molecular biology 1993;44(4-6):605-9.
1993: T J Iveson; Ian E Smith; J Ahern; D A Smithers; P F Trunet; M Dowsett
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer.
Cancer research 1993;53(2):266-70.
1993: T J Iveson; J Ahern; Ian E Smith
Response to third-line endocrine treatment for advanced breast cancer.
European journal of cancer (Oxford, England : 1990) 1993;29A(4):572-4.
1993: Denis C Talbot; Ian E Smith; M C Nicolson; Trevor J Powles; D Button; J Walling
Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer.
Cancer chemotherapy and pharmacology 1993;31(5):419-22.
1993: M J Everard; V M Macaulay; J L Millar; Ian E Smith
[D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P inhibits the growth of human small cell lung cancer xenografts in vivo.
European journal of cancer (Oxford, England : 1990) 1993;29A(10):1450-3.
1992: A L Jones; Trevor J Powles; M Law; Alwynne Tidy; Douglas Easton; R C Coombes; Ian E Smith; J A McKinna; A Nash; H T Ford
Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(10):1547-52.
1992: S R Johnston; Mitch Dowsett; Ian E Smith
Towards a molecular basis for tamoxifen resistance in breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(7):503-11.
1992: Ian E Smith; Denis C Talbot
Cisplatin and its analogues in the treatment of advanced breast cancer: a review.
British journal of cancer 1992;65(6):787-93.
1992: K M Fife; Denis C Talbot; P Mortimer; C Fisher; Ian E Smith
Chylous ascites in Kaposi's sarcoma: a case report.
The British journal of dermatology 1992;126(4):378-9.
1992: M J Everard; V M Macaulay; J L Miller; Ian E Smith
In vitro effects of substance P analogue [D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P on human tumour and normal cell growth.
British journal of cancer 1992;65(3):388-92.
1992: Denis C Talbot; Ian E Smith
New perspectives in lung cancer.5. New drugs in lung cancer.
Thorax 1992;47(3):188-94.
1992: Ian E Smith
Carboplatin in small cell lung cancer: the Royal Marsden Hospital experience.
Seminars in oncology 1992;19(1 Suppl 2):24-7.
1992: Mitch Dowsett; S Jacobs; J Aherne; Ian E Smith
Clinical and endocrine effects of leuprorelin acetate in pre- and postmenopausal patients with advanced breast cancer.
Clinical therapeutics 1992;14 Suppl A():97-103.
1992: Mitch Dowsett; A Mehta; N King; Ian E Smith; Trevor J Powles; R C Stein; R C Coombes
An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients.
European journal of cancer (Oxford, England : 1990) 1992;28(2-3):415-20.
1991: Denis C Talbot; Ian E Smith; J L Mansi; I Judson; A Hilary Calvert; SE Ashley
Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(12):2141-7.
1991: V M Macaulay; Ian E Smith; M J Everard; J D Teale; J C Reubi; JL Millar
Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer.
British journal of cancer 1991;64(3):451-6.
1991: D I Jodrell; Ian E Smith; J L Mansi; M C Pearson; Geraldine Walsh; Sue Ashley; H D Sinnett; J A McKinna
A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.
British journal of cancer 1991;63(5):794-8.
1991: F Adshead; A De Graeff; J L Mansi; D M Thomas; Ian E Smith
Small cell carcinoma of the prostate: implications for management.
British journal of urology 1991;67(2):217-8.
1991: A L Jones; J Holborn; Sue Ashley; Ian E Smith
Effective new low toxicity chemotherapy with carboplatin, vinblastine and methotrexate for small cell lung cancer: a randomised trial against doxorubicin, cyclophosphamide and etoposide.
European journal of cancer (Oxford, England : 1990) 1991;27(7):866-70.
1990: Mitch Dowsett; A Mehta; J Mansi; Ian E Smith
A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients.
British journal of cancer 1990;62(5):834-7.
1990: Ian E Smith; T J Perren; S A Ashley; J Woodiwiss; G V Forgeson; J R Yarnold; H T Ford
Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(5):899-905.
1990: V M Macaulay; M J Everard; J D Teale; P A Trott; Judson Vanwyk; Ian E Smith; JL Millar
Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells.
Cancer research 1990;50(8):2511-7.
1990: M J Everard; V M Macaulay; Toon Min; J L Millar; Ian E Smith
Small cell lung cancer cell line from histologically and immunocytochemically negative bone marrow.
European journal of cancer (Oxford, England : 1990) 1990;26(6):766-7.
1990: D I Jodrell; Ian E Smith
Carboplatin in the treatment of metastatic carcinoid tumours and paraganglioma: a phase II study.
Cancer chemotherapy and pharmacology 1990;26(1):62-4.
1989: J L Mansi; Ian E Smith; Geraldine Walsh; Roger A'Hern; C L Harmer; H D Sinnett; PA Trott; C Fisher; J A McKinna
Primary medical therapy for operable breast cancer.
European journal of cancer & clinical oncology 1989;25(11):1623-7.
1989: J R Hardy; T Noble; Ian E Smith
Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer.
British journal of cancer 1989;60(5):764-6.
1989: I L Crighton; M Dowsett; A Lal; A Man; Ian E Smith
Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects.
British journal of cancer 1989;60(4):644-8.
1988: D I Jodrell; A T Irvine; V Ralph McCready; E Woodcraft; Ian E Smith
The use of 131I-MIBG in the imaging of metastatic carcinoid tumours.
British journal of cancer 1988;58(5):663-4.
1988: V M Macaulay; J D Teale; M J Everard; G P Joshi; JL Millar; Ian E Smith
Serum insulin-like growth factor-I levels in patients with small cell lung cancer.
European journal of cancer & clinical oncology 1988;24(7):1241-2.
1988: V M Macauly; J D Teale; M J Everard; G P Joshi; Ian E Smith; JL Millar
Somatomedin-C/insulin-like growth factor-I is a mitogen for human small cell lung cancer.
British journal of cancer 1988;57(1):91-3.
1987: C J Gallagher; F Cairnduff; Ian E Smith
High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer.
European journal of cancer & clinical oncology 1987;23(12):1895-900.
1987: V Macaulay; G P Joshi; M Everard; Ian E Smith; J L Millar
A high molecular weight non-bombesin/gastrin releasing peptide growth factor in small cell lung cancer.
British journal of cancer 1987;56(6):791-4.
1987: mark vincent; SE Ashley; Ian E Smith
Prognostic factors in small cell lung cancer: a simple prognostic index is better than conventional staging.
European journal of cancer & clinical oncology 1987;23(11):1589-99.
1983: Ian E Smith; A L Harris; R Stuart-Harris; H T Ford; J C Gazet; H White; C L Harmer; L Carr; J A McKinna; M Morgan
Combination treatment with tamoxifen and aminoglutethimide in advanced breast cancer.
British medical journal (Clinical research ed.) 1983;286(6378):1615-6.
1983: A L Harris; Trevor J Powles; Ian E Smith; R Charles Coombes; H T Ford; J C Gazet; C L Harmer; M Morgan; H White; C A Parsons; J A McKinna
Aminoglutethimide for the treatment of advanced postmenopausal breast cancer.
European journal of cancer & clinical oncology 1983;19(1):11-17.
1981: Ian E Smith; A L Harris; M Morgan; H T Ford; J C Gazet; C L Harmer; H White; C A Parsons; A Villardo; G Walsh; J A McKinna
Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial.
British medical journal (Clinical research ed.) 1981;283(6304):1432-4.
1980: Ian E Smith; R Charles Coombes; H T Ford; J C Gazet; C Harmer; M Jones; J A McKinna; Trevor J Powles
Aminoglutethimide in the management of advanced breast cancer.
European journal of cancer 1980;Suppl 1():99-101.
1980: P J Dady; R Charles Coombes; Ian E Smith; C A Parsons; H T Ford; J C Gazet; J M Henk; A G Nash; Trevor J Powles
Use of an antiosteolytic agent in treatment of patients with bone metastases from breast cancer.
European journal of cancer 1980;Suppl 1():131-5.